Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Pituitary gland: Medical therapy for acromegaly: can we predict response?

Giustina A, Porcelli T.

Nat Rev Endocrinol. 2009 Aug;5(8):425-7. doi: 10.1038/nrendo.2009.146.

PMID:
19629067
2.

Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.

Sherlock M, Fernandez-Rodriguez E, Alonso AA, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM.

J Clin Endocrinol Metab. 2009 Apr;94(4):1255-63. doi: 10.1210/jc.2008-1420. Epub 2009 Jan 21.

PMID:
19158203
3.

Efficacy and safety of radiotherapy in acromegaly.

González B, Vargas G, Espinosa-de-los-Monteros AL, Sosa E, Mercado M.

Arch Med Res. 2011 Jan;42(1):48-52. doi: 10.1016/j.arcmed.2011.01.004.

PMID:
21376263
4.

Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society.

Growth Hormone Research Society; Pituitary Society.

J Clin Endocrinol Metab. 2004 Jul;89(7):3099-102. Review. No abstract available.

PMID:
15240576
5.

Consensus statement: medical management of acromegaly.

Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A.

Eur J Endocrinol. 2005 Dec;153(6):737-40.

6.

[Novel pharmacologic therapies in acromegaly].

Góth M, Hubina E, Kovács L, Szabolcs I.

Orv Hetil. 2002 May 12;143(19 Suppl):1057-62. Review. Hungarian.

PMID:
12063860
7.

Current and future medical treatments for patients with acromegaly.

Maffezzoni F, Formenti AM, Mazziotti G, Frara S, Giustina A.

Expert Opin Pharmacother. 2016 Aug;17(12):1631-42. doi: 10.1080/14656566.2016.1199687. Epub 2016 Jun 28. Review.

PMID:
27352098
8.

Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists.

Howlett TA, Willis D, Walker G, Wass JA, Trainer PJ; UK Acromegaly Register Study Group (UKAR-3).

Clin Endocrinol (Oxf). 2013 Nov;79(5):689-99. doi: 10.1111/cen.12207. Epub 2013 Apr 24.

PMID:
23574573
9.

Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.

Waśko R, Ruchała M, Sawicka J, Kotwicka M, Liebert W, Sowiński J.

J Endocrinol Invest. 2000 Jan;23(1):12-8.

PMID:
10698045
10.

[Optimization of the medical treatment for acromegaly].

Díez JJ, Iglesias P.

Med Clin (Barc). 2013 Apr 20;140(8):360-5. doi: 10.1016/j.medcli.2012.07.024. Epub 2012 Oct 26. Review. Spanish.

PMID:
23103101
11.

[Therapeutic management of acromegaly].

Metzner C, Hadziselimovic S, Grafe I, Nawroth P, Kasperk C.

Med Klin (Munich). 2006 Jan 15;101(1):15-23. Review. German.

PMID:
16418810
12.

Management of endocrine disease: GH excess: diagnosis and medical therapy.

Andersen M.

Eur J Endocrinol. 2013 Nov 29;170(1):R31-41. doi: 10.1530/EJE-13-0532. Print 2014 Jan. Review.

13.

Pharmacological management of acromegaly: a current perspective.

Manjila S, Wu OC, Khan FR, Khan MM, Arafah BM, Selman WR.

Neurosurg Focus. 2010 Oct;29(4):E14. doi: 10.3171/2010.7.FOCUS10168. Review.

PMID:
20887124
14.

Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.

Arihara Z, Sakurai K, Yamashita R, Niitsuma S, Ueno T, Yamamura N, Yamada S, Inoshita N, Takahashi K.

Tohoku J Exp Med. 2014 Oct;234(2):129-35.

15.

The place of pegvisomant in the acromegaly treatment algorithm.

Paisley AN, Trainer PJ, Drake WM.

Growth Horm IGF Res. 2004 Jun;14 Suppl A:S101-6. Review.

PMID:
15135788
16.

In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.

Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A.

Clin Endocrinol (Oxf). 2001 Apr;54(4):469-77.

PMID:
11318782
17.

Medical therapy in acromegaly.

Sherlock M, Woods C, Sheppard MC.

Nat Rev Endocrinol. 2011 May;7(5):291-300. doi: 10.1038/nrendo.2011.42. Epub 2011 Mar 29. Review.

PMID:
21448141
18.

Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly.

Selvarajah D, Webster J, Ross R, Newell-Price J.

Eur J Endocrinol. 2005 Apr;152(4):569-74.

19.

Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.

Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P, Beckers A.

Eur J Endocrinol. 2005 Jan;152(1):61-6.

20.

Somatostatin analogs in medical treatment of acromegaly.

Racine MS, Barkan AL.

Endocrine. 2003 Apr;20(3):271-8. Review.

PMID:
12721507

Supplemental Content

Support Center